##common.pageHeaderLogo.altText##

Original article

Vol. 156 No. 2 (2026)

Efficacy and safety of bulevirtide in patients with chronic hepatitis D treated under early access in Switzerland: a retrospective analysis

Cite this as:
Swiss Med Wkly. 2026;156:4736
Published
23.02.2026

Summary

 

BACKGROUND AND AIMS: Bulevirtide 2 mg/day was approved in Switzerland in February 2025 for the treatment of chronic hepatitis D virus (HDV) infection. We present real-world data on efficacy and safety in patients treated under an early access programme.

METHODS: This retrospective, multicentre Swiss cohort study included patients with compensated HDV-associated cirrhosis in whom bulevirtide therapy (2 mg/day) was initiated between January 2020 and August 2024 under a compassionate use programme. Virological response was defined as a HDV RNA level that was undetectable or declined ≥2 log10 IU/ml from baseline. Biochemical response was defined as normalisation of ALT. Combined response was defined as achieving both virological and biochemical response. Liver-related events and adverse events were assessed.

RESULTS: Fourteen patients with compensated HDV-related cirrhosis received bulevirtide for a median duration of 1.85 years (1.1–2.1). Median age was 51.3 years (43.9–58.5), and 71.4% were men. Baseline ALT was 81 U/l (55.8–88.8), platelet count 102.5 × 109/l (67.3–141.3) and liver stiffness 15.3 kPa (11.8–22.1). Baseline HDV RNA was 4.82 log10 IU/ml (4.52–6.23). Biochemical, virological and combined responses were observed in 50%, 64.3% and 35.7% at 6 months; 66.7%, 75% and 58.3% at 12 months; and 62.5% for all three response types at 24 months. Two patients (14.3%) developed de novo hepatocellular carcinoma, and one (7.14%) patient underwent liver transplantation. No serious adverse events were reported. Mild transient pruritus occurred in two (14.3%) patients.

CONCLUSIONS: In this real-world cohort of patients with compensated HDV cirrhosis, bulevirtide demonstrated favourable efficacy and safety. These findings support the integration of bulevirtide into routine care for patients with HDV and compensated cirrhosis in Switzerland following its reimbursement status as of 2025. Longer-term follow-up is warranted to assess the impact on liver-related outcomes.

References

  1. 1. Brunetto MR, Ricco G, Negro F, Wedemeyer H, Yurdaydin C, Asselah T, et al.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433–60. doi: https://doi.org/10.1016/j.jhep.2023.05.001
  2. 2. Stockdale AJ, Kreuels B, Henrion MY, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020 Sep;73(3):523–32. doi: https://doi.org/10.1016/j.jhep.2020.04.008
  3. 3. Miao Z, Zhang S, Ou X, Li S, Ma Z, Wang W, et al. Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis. 2020 Apr;221(10):1677–87. doi: https://doi.org/10.1093/infdis/jiz633
  4. 4. Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, et al.; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019 Mar;19(3):275–86. doi: https://doi.org/10.1016/S1473-3099(18)30663-7
  5. 5. Wedemeyer H, Schöneweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023 Jan;23(1):117–29. doi: https://doi.org/10.1016/S1473-3099(22)00318-8
  6. 6. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016 Sep;65(3):490–8. doi: https://doi.org/10.1016/j.jhep.2016.04.016
  7. 7. Asselah T, Chulanov V, Lampertico P, Wedemeyer H, Streinu-Cercel A, Pântea V, et al. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. N Engl J Med. 2024 Jul;391(2):133–43. doi: https://doi.org/10.1056/NEJMoa2314134
  8. 8. Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, et al. Bulevirtide monotherapy in patients with chronic HDV: efficacy and safety results through week 96 from a phase III randomized trial. J Hepatol. 2024 Oct;81(4):621–9. doi: https://doi.org/10.1016/j.jhep.2024.05.001
  9. 9. Degasperi E, Anolli MP, Jachs M, Reiberger T, De Ledinghen V, Metivier S, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol. 2025 Jun;82(6):1012–22. doi: https://doi.org/10.1016/j.jhep.2024.12.044
  10. 10. Archer AJ, Belfield KJ, Orr JG, Gordon FH, Abeysekera KW. EASL clinical practice guidelines: non-invasive liver tests for evaluation of liver disease severity and prognosis. Frontline Gastroenterol. 2022 Feb;13(5):436–9. doi: https://doi.org/10.1136/flgastro-2021-102064
  11. 11. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol. 2003 Apr;38(4):427–32. doi: https://doi.org/10.1080/00365520310000825
  12. 12. Takyar V, Surana P, Kleiner DE, Wilkins K, Hoofnagle JH, Liang TJ, et al. Noninvasive markers for staging fibrosis in chronic delta hepatitis. Aliment Pharmacol Ther. 2017 Jan;45(1):127–38. doi: https://doi.org/10.1111/apt.13834
  13. 13. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002 Oct;97(10):2614–8. doi: https://doi.org/10.1111/j.1572-0241.2002.06038.x